NCT00088868View on ClinicalTrials.gov

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2010

Study Completion Date

December 31, 2010

Conditions
LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

alvespimycin hydrochloride

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00088868 - 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma | Biotech Hunter | Biotech Hunter